Recent Updates
Recently added Catalysts
QGEN Positive Sentiment

QIAGEN reports preliminary Q3 2026 results

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: QIAGEN N.V. reported preliminary financial results for Q3 2026, showing net sales of $548 million and adjusted diluted earnings per share of $0.65. These figures were consistent at both reported and constant exchange rates. The company plans to release full results on November 4, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Net sales reached $548 million.
  • Adjusted diluted EPS was $0.65.
  • Results met expectations at constant exchange rates.

Full Press Release Details

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER. QIAGEN plans to report full Q3 2026 results on Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time / 16:05 New York time. Given the announced transaction wit

Frequently Asked Questions

What were QIAGEN's net sales for Q3 2026?

Net sales for Q3 2026 were $548 million.

What was the adjusted EPS for QIAGEN in Q3 2026?

The adjusted diluted EPS was $0.65.

When will QIAGEN report full Q3 2026 results?

Full results will be reported on November 4, 2026.

Did QIAGEN's results meet expectations?

Yes, results were consistent at constant exchange rates.

ShareAdd on Google
Tags: QGEN QIAGEN Q3 2026 financial results net sales earnings per share
Last updated: Oct 21, 2026